Skip to content
Guide

Pharmacogenomics in India: How Your Genes Affect Medications

Pharmacogenomics predicts how your genes affect the way you respond to medicines. Learn key gene-drug pairs, Indian relevance, cost and what a PGx test shows.

The Meridian Clinical Team Medically reviewed by Meridian Medical Review Board 3 min readUpdated 6 July 2026

Pharmacogenomics (PGx) is the science of how your genes shape the way your body processes and responds to medicines. Because everyone inherits different versions of drug-metabolising genes, the same drug at the same dose can help one person, do nothing for another, and cause side effects in a third. A PGx test reads those genes so your doctor can prescribe more precisely.

What pharmacogenomics actually is

Most medicines are broken down (metabolised) by a small family of liver enzymes. The genes that build those enzymes come in different versions, or variants. Depending on which variants you carry, you may be a:

  • Poor metaboliser: the drug clears slowly and can build up, raising the risk of side effects.
  • Intermediate metaboliser: somewhat reduced processing.
  • Normal metaboliser: the expected, typical response.
  • Rapid or ultrarapid metaboliser: the drug clears fast, and a standard dose may not work, or a "prodrug" may be over-activated.

Pharmacogenomics turns those categories into practical guidance. It does not predict every drug or every reaction, but for a well-studied set of gene-drug pairs, it meaningfully improves the odds of getting the right medicine the first time.

How genes change drug response

There are two broad ways your genes matter:

  1. Metabolism: how fast you activate or clear a drug (mostly the CYP enzyme family, plus transporters like SLCO1B1).
  2. Response and safety: how your body reacts, including risk of severe reactions (for example TPMT and NUDT15 with thiopurines, or HLA variants with certain drugs).

This is why two patients on the same antidepressant, statin, or blood thinner can have completely different experiences. The difference is often written in their DNA.

Key gene-drug pairs your doctor can use

These are the best-established, guideline-backed examples, the ones supported by CPIC and PharmGKB:

GeneAffected medicinesWhy it matters
CYP2C19Clopidogrel (Plavix), some antidepressantsPoor metabolisers may not activate clopidogrel well after a stent, reducing its protection
CYP2D6Codeine, tramadol, several antidepressantsAlters pain relief and antidepressant levels; ultrarapid metabolisers risk codeine toxicity
SLCO1B1Statins (especially simvastatin)Reduced-function variants raise blood levels and the risk of muscle side effects (myopathy)
TPMT / NUDT15Thiopurines (azathioprine, 6-mercaptopurine)Deficiency can cause dangerous bone-marrow suppression; dose must be lowered
VKORC1 / CYP2C9WarfarinTogether they explain much of the wide variation in the correct warfarin dose

For a plain-language walkthrough of the science, see what is pharmacogenomics.

Why pharmacogenomics matters especially in India

Drug-gene frequencies differ by ancestry, and Indian populations are not the same as the European populations most drug labels were built around. The clearest example is NUDT15: variants that make thiopurine drugs dangerous are much more common in South and East Asian people. An Indian patient started on standard-dose azathioprine without NUDT15 testing can suffer a severe fall in white blood cells.

CYP2C19 reduced-function variants, relevant to clopidogrel after cardiac stents, are also common across Indian populations. Given how many Indians are prescribed clopidogrel after a heart attack, this is not a niche concern.

What a Meridian PGx test shows

A pharmacogenomic report translates your genotype into clear, doctor-ready guidance:

  • Your metaboliser status for each tested gene.
  • The medicines affected, grouped by specialty (cardiology, psychiatry, pain, gastroenterology and more).
  • Plain flags, "standard dose expected to work", "consider alternative", "use with caution".

It is a reference your doctor keeps for life. Because your DNA does not change, one test informs prescribing decisions for decades.

Crucially, the report guides: it does not prescribe. Never change or stop a medicine based on a PGx report on your own. Bring it to your doctor, who decides. Meridian includes a free doctor consultation to help you do exactly that.

Who benefits most

  • Anyone starting or struggling with antidepressants after trial-and-error, see will this medicine work for me.
  • Heart patients prescribed clopidogrel after a stent.
  • People starting statins who develop muscle aches, see statin genetic testing.
  • Patients with IBD, autoimmune disease or leukaemia facing thiopurines (TPMT/NUDT15).
  • Anyone on multiple long-term medications who wants fewer surprises.

Cost and turnaround

At Meridian, the essential pharmacogenomics panel is ₹9,500 and the advanced panel is around ₹17,000. Testing is run in a CAP-grade lab, reports arrive in about 14 working days, and every result includes a free consultation.

Ready to explore it? Learn more about the medication response test, or read the deeper articles below.

This article is for education, not medical diagnosis. Genetic results describe risk and tendencies, not certainty. Always discuss testing and results with a qualified doctor.

Meridian test

Medication Response

One DNA test that shows how your body responds to 100+ common medicines, for life.

₹9,500Learn about the test →

Frequently asked questions

Pharmacogenomics (PGx) is the study of how your genes affect the way your body handles and responds to medicines. Because we each carry different versions of drug-metabolising genes, the same dose can be too strong for one person and too weak for another. A PGx test reads these genes to help your doctor choose safer drugs and doses.

Start today

Your DNA won't change.
The decisions you make can.

The most personalized health plan you'll ever have is already inside you. Explore the tests and turn it into a longer, healthier life.